We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New AACC Procalcitonin Testing Guidance to Improve Care for Patients with Bacterial Infections

By LabMedica International staff writers
Posted on 08 May 2023
Print article
Illustration
Illustration

Although procalcitonin tests have been employed in Europe for years, they were only introduced in the U.S. in 2017 when the FDA approved their use for guiding antibiotic treatment and predicting the likelihood of death within 28 days for sepsis patients. Given their recent arrival in the U.S., there remains uncertainty about the appropriate use of these tests, which are sometimes ordered in clinically inapplicable situations. To address this issue, new guidance offers a comprehensive analysis of procalcitonin research and its limitations, aiming to improve testing and treatment practices.

The American Association for Clinical Chemistry (AACC, Washington, DC, USA) has released expert guidance on procalcitonin testing, a blood marker used to detect severe bacterial infections and sepsis. This guidance aims to provide clarity for clinicians and laboratory professionals, enhancing the treatment of critically ill patients and those with specific lower respiratory infections. The document tackles key questions related to procalcitonin usage in managing adult, pediatric, and newborn patients with suspected sepsis and/or bacterial infections, especially those affecting the lower respiratory tract. It also examines the evidence for using these tests to inform antimicrobial treatment decisions and predict patient outcomes.

There is strong evidence supporting procalcitonin testing in guiding clinicians on when to discontinue antibiotic treatment in critically ill patients and those with certain lower respiratory tract infections. The AACC guidance suggests incorporating procalcitonin testing into comprehensive antimicrobial stewardship efforts, involving multidisciplinary teams. Some studies indicate that procalcitonin levels can also help determine when to stop antibiotics in newborns and pediatric patients with suspected sepsis who exhibit clinical improvement. However, the guidance authors believe these studies are insufficient in size to establish standard levels applicable across pediatric populations, given that procalcitonin reference intervals were established for adults. Consequently, if procalcitonin testing is used for these groups, it is important to define pediatric reference intervals or interpretive criteria.

Despite the FDA's approval of procalcitonin tests for predicting 28-day mortality risk in sepsis patients, the guidance does not recommend their routine use for this purpose. This is due to inconsistent procalcitonin cut-offs and clearance parameters, as well as a lack of substantial evidence demonstrating the benefit of estimating 28-day mortality risk for patients with sepsis and lower respiratory tract infections.

"Improved outcomes from [procalcitonin] implementation are more likely to be realized when the test is used in conjunction with antimicrobial stewardship programs, institutional interpretive algorithms, and clinical decision support tools," said the guidance document authors Drs. Allison B. Chambliss, Khushbu Patel, Jessica M. Colón-Franco, Joshua Hayden, Sophie E. Katz, Emi Minejima, and Alison Woodworth. "Successful implementation of clinical [procalcitonin] requires a multidisciplinary effort among laboratorians, pharmacists, and infectious disease providers."

 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.